KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. Budczies J, Romanovsky E, Kirchner M, Neumann O, et al. Br J Cancer 2024;131:524-533.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Budczies J, Romanovsky E, Kirchner M, Neumann O, et al. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. Br J Cancer 2024;131:524-533.
PMID: 38866964